Smartphone App to Self-Monitor Nausea During Pediatric Chemotherapy Treatment: User-Centered Design Process.
antiemetics
app
cancer
children
mobile applications
nausea
neoplasms
patient compliance
patient-reported outcome measures
vomiting
Journal
JMIR mHealth and uHealth
ISSN: 2291-5222
Titre abrégé: JMIR Mhealth Uhealth
Pays: Canada
ID NLM: 101624439
Informations de publication
Date de publication:
20 07 2020
20 07 2020
Historique:
received:
05
03
2020
accepted:
13
05
2020
revised:
23
04
2020
entrez:
25
7
2020
pubmed:
25
7
2020
medline:
7
4
2021
Statut:
epublish
Résumé
Nausea and vomiting are common and distressing side effects for children receiving chemotherapy. Limited evidence is available to guide antiemetic recommendations; therefore, prospective and reliable evaluation of antiemetic efficacy is needed. Smartphone apps can be used to effortlessly and precisely collect patient-reported outcomes in real time. Our objective was to develop a smartphone app to monitor nausea and vomiting episodes in pediatric cancer patients aged 0 to 18 years and to test its usability and adherence to its use. We used a user-centered design process and the evolutionary prototype model to develop and evaluate the app. Multidisciplinary group discussions and several rounds of patient feedback and modification were conducted. We translated the validated Pediatric Nausea Assessment Tool to assess nausea severity in children aged 4 to 18 years. The child's own term for nausea was interactively incorporated in the nausea severity question, with response options expressed as 4 illustrative faces. Parent-reported outcomes were used for children aged 0 to 3 years. Reminders were sent using push notifications in order to ensure high response rates. Children aged 0 to 18 years who were undergoing chemotherapy were recruited from the Department of Pediatric Oncology at Copenhagen University Hospital Rigshospitalet to evaluate the app. The app's most important function was to record nausea severity in children. After assistance from a researcher, children aged 4 to 18 years were able to report their symptoms in the app, and parents were able to report symptoms for their children aged 0 to 3 years. Children (n=20, aged 2.0-17.5 years) and their parents evaluated the app prospectively during a collective total of 60 chemotherapy cycles. They expressed that the app was user-friendly, intuitive, and that the time spent on data entry was fair. The response rates were on average 92%, 93%, and 80% for the day before, the first day of, and the next 3 days after chemotherapy, respectively. Researchers and clinicians were able to obtain an overview of the patient's chemotherapy dates and responses through a secure and encrypted web-based administrative portal. Data could be downloaded for further analysis. The user-friendly app could be used to facilitate future pediatric antiemetic trials and to refine antiemetic treatment during chemotherapy.
Sections du résumé
BACKGROUND
Nausea and vomiting are common and distressing side effects for children receiving chemotherapy. Limited evidence is available to guide antiemetic recommendations; therefore, prospective and reliable evaluation of antiemetic efficacy is needed. Smartphone apps can be used to effortlessly and precisely collect patient-reported outcomes in real time.
OBJECTIVE
Our objective was to develop a smartphone app to monitor nausea and vomiting episodes in pediatric cancer patients aged 0 to 18 years and to test its usability and adherence to its use.
METHODS
We used a user-centered design process and the evolutionary prototype model to develop and evaluate the app. Multidisciplinary group discussions and several rounds of patient feedback and modification were conducted. We translated the validated Pediatric Nausea Assessment Tool to assess nausea severity in children aged 4 to 18 years. The child's own term for nausea was interactively incorporated in the nausea severity question, with response options expressed as 4 illustrative faces. Parent-reported outcomes were used for children aged 0 to 3 years. Reminders were sent using push notifications in order to ensure high response rates. Children aged 0 to 18 years who were undergoing chemotherapy were recruited from the Department of Pediatric Oncology at Copenhagen University Hospital Rigshospitalet to evaluate the app.
RESULTS
The app's most important function was to record nausea severity in children. After assistance from a researcher, children aged 4 to 18 years were able to report their symptoms in the app, and parents were able to report symptoms for their children aged 0 to 3 years. Children (n=20, aged 2.0-17.5 years) and their parents evaluated the app prospectively during a collective total of 60 chemotherapy cycles. They expressed that the app was user-friendly, intuitive, and that the time spent on data entry was fair. The response rates were on average 92%, 93%, and 80% for the day before, the first day of, and the next 3 days after chemotherapy, respectively. Researchers and clinicians were able to obtain an overview of the patient's chemotherapy dates and responses through a secure and encrypted web-based administrative portal. Data could be downloaded for further analysis.
CONCLUSIONS
The user-friendly app could be used to facilitate future pediatric antiemetic trials and to refine antiemetic treatment during chemotherapy.
Identifiants
pubmed: 32706744
pii: v8i7e18564
doi: 10.2196/18564
pmc: PMC7400028
doi:
Types de publication
Clinical Trial, Phase III
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e18564Informations de copyright
©Astrid Eliasen, Mikkel Kramme Abildtoft, Niels Steen Krogh, Catherine Rechnitzer, Jesper Sune Brok, René Mathiasen, Kjeld Schmiegelow, Kim Peder Dalhoff. Originally published in JMIR mHealth and uHealth (http://mhealth.jmir.org), 20.07.2020.
Références
Pharmacotherapy. 2006 Sep;26(9):1221-31
pubmed: 16945043
Bone Marrow Transplant. 2017 Sep;52(9):1294-1299
pubmed: 28581463
J Clin Oncol. 2017 Oct 1;35(28):3240-3261
pubmed: 28759346
Support Care Cancer. 2015 Nov;23(11):3229-37
pubmed: 25851802
J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32
pubmed: 19920223
JMIR Mhealth Uhealth. 2019 Oct 29;7(10):e12586
pubmed: 31663862
Support Care Cancer. 2016 Mar;24(3):1365-71
pubmed: 26335406
J Med Internet Res. 2013 Mar 08;15(3):e51
pubmed: 23475457
JMIR Res Protoc. 2017 May 23;6(5):e99
pubmed: 28536095
Crit Rev Oncol Hematol. 2020 May;149:102939
pubmed: 32259776
Control Clin Trials. 2003 Apr;24(2):182-99
pubmed: 12689739
Ugeskr Laeger. 2018 Aug 27;180(35):
pubmed: 30152323
CA Cancer J Clin. 2012 Sep-Oct;62(5):337-47
pubmed: 22811342
Cochrane Database Syst Rev. 2016 Feb 02;2:CD007786
pubmed: 26836199
Lancet Oncol. 2016 Mar;17(3):332-344
pubmed: 26795844
J Pediatr Oncol Nurs. 2003 May-Jun;20(3):120-32
pubmed: 12776260
Nat Rev Clin Oncol. 2016 May;13(5):319-25
pubmed: 26787278
JMIR Form Res. 2019 Apr 22;3(2):e12028
pubmed: 31008704
Stud Health Technol Inform. 2017;245:253-257
pubmed: 29295093
Support Care Cancer. 2018 Nov;26(11):3721-3728
pubmed: 29732483
JMIR Cancer. 2018 Dec 21;4(2):e10932
pubmed: 30578238
Support Care Cancer. 2017 Jan;25(1):323-331
pubmed: 27565788
Health Qual Life Outcomes. 2007 Jan 03;5:2
pubmed: 17201923
JMIR Cancer. 2019 Jul 31;5(2):e12071
pubmed: 31368438
Pediatr Blood Cancer. 2017 Oct;64(10):
pubmed: 28453189
Lancet Oncol. 2006 Nov;7(11):903-9
pubmed: 17081915
Headache. 2001 Jan;41(1):11-20
pubmed: 11168599
Lancet Oncol. 2015 Apr;16(4):385-94
pubmed: 25770814
N Engl J Med. 2010 Mar 11;362(10):865-9
pubmed: 20220181
J Clin Epidemiol. 2007 Jan;60(1):8-17
pubmed: 17161749
Cancer Nurs. 2012 May-Jun;35(3):203-10
pubmed: 21915041
J Med Internet Res. 2020 Mar 25;22(3):e12689
pubmed: 32209536